S950 Symptomology Following SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease Relative to Healthcare Workers

Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis

“…Eventually, 9 studies (8 full texts and one abstract) with 16 cohorts were included in the final analysis. The details of the included studies are illustrated in Table 1 [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] . The details of the excluded studies with the reason for exclusion is shown in Supplementary Table 2 [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] .…”

“…The quality analysis of the included studies was done using Newcastle-Ottawa Quality Assessment Form for Cohort Studies. The results of the assessment are shown in Supplementary Table 3 [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] . Of the included studies, two studies were of good quality, three studies were of fair quality and four studies were of poor quality.…”